Mobile CT Viewer Application Designed for Diagnostic Image Viewing on iPads

A new software application for diagnostic image viewing on the iPad has been designed for use anytime, anywhere medical image viewing, sharing, and collaboration, improving imaging workflow for physicians and other healthcare providers, which lowers costs, helps patients participate in their health, and enhances care.

Nephosity, Inc. (San Francisco, CA, USA), a digital health startup company, has received clearance from the United States Food and Drug Administration (FDA) for their MobileCT Viewer. This FDA 510(k) clearance confirms the effectiveness and safety of MobileCT Viewer, and allows for diagnostic viewing of magnetic resonance imaging (MRI), computed tomography (CT), and X-ray medical images by trained professionals on the iPad, developed by Apple, Inc. (Cupertino, CA, USA), in settings where there is no access to a workstation.

MobileCT Viewer’s many features include: image manipulation such as window and level, pan and zoom; full resolution images, ensuring that no detail is lost; HIPAA (Health Insurance Portability and Accountability Act of 1996) compliance, with SSL (secure sockets layer) encryption for all information in-transit and 256-bit AES (Advanced Encryption Standard) encryption for all patient data at rest; measurement of distances, display measurements and annotations; and lastly, Verify Lighting Check, which guides the user to determine whether the environmental lighting conditions can accommodate a diagnosis.

Nephosity will now integrate the FDA-cleared MobileCT Viewer into its medical image platform so that physicians can view images diagnostically and collaboratively. Moreover, Nephosity will extend the devices and platforms on which MobileCT Viewer will run and submit supplementary applications for clearance of clinical diagnostic imaging on devices not already cleared by the FDA.

Nephosity offers a nondiagnostic version of its collaborative medical image viewer technology for Mac OS X, Windows, and Android platforms.

Related Links:
Nephosity